Alfavision Overseas (India) Limited (ALFAVIO.BO)
INR 14.4
(0.84%)
INR 14.4
(0.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 10.12 Million INR | 293.25% |
| 2022 | 22.77 Million INR | -114.34% |
| 2021 | 61.6 Million INR | 26.15% |
| 2020 | 49.34 Million INR | -13.78% |
| 2019 | 33.32 Million INR | 35.74% |
| 2018 | 24.95 Million INR | 11.15% |
| 2017 | 21.23 Million INR | 455.0% |
| 2016 | 6.89 Million INR | -27.16% |
| 2015 | 5.31 Million INR | 15.35% |
| 2014 | 4.57 Million INR | 44.75% |
| 2013 | 3.31 Million INR | 16.07% |
| 2012 | 2.69 Million INR | 361.64% |
| 2011 | -1.02 Million INR | -218.51% |
| 2010 | 868 Thousand INR | -28.97% |
| 2009 | 1.22 Million INR | -65.56% |
| 2008 | 3.54 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 957 Thousand INR | 114.62% |
| 2023 Q4 | -7.97 Million INR | -1185.97% |
| 2023 Q3 | -620 Thousand INR | -112.1% |
| 2023 Q2 | 5.12 Million INR | -57.99% |
| 2023 Q1 | 12.2 Million INR | 123.46% |
| 2023 FY | - INR | 293.25% |
| 2022 Q2 | 11.91 Million INR | 75.87% |
| 2022 Q3 | 7.22 Million INR | -39.39% |
| 2022 Q4 | -52 Million INR | -819.93% |
| 2022 Q1 | 6.77 Million INR | -38.37% |
| 2022 FY | - INR | -114.34% |
| 2021 Q4 | 10.99 Million INR | 167.67% |
| 2021 Q1 | 3.95 Million INR | -79.19% |
| 2021 Q3 | 4.1 Million INR | -60.87% |
| 2021 Q2 | 10.49 Million INR | 165.19% |
| 2021 FY | - INR | 26.15% |
| 2020 Q2 | 3.7 Million INR | -48.76% |
| 2020 FY | - INR | -13.78% |
| 2020 Q1 | 7.22 Million INR | 21.0% |
| 2020 Q3 | 17.1 Million INR | 361.98% |
| 2020 Q4 | 19.02 Million INR | 11.2% |
| 2019 FY | - INR | 35.74% |
| 2019 Q1 | 7.2 Million INR | -55.63% |
| 2019 Q2 | 8.03 Million INR | 11.49% |
| 2019 Q3 | 11.23 Million INR | 39.84% |
| 2019 Q4 | 5.97 Million INR | -46.82% |
| 2018 Q1 | 2.78 Million INR | 1438.46% |
| 2018 FY | - INR | 11.15% |
| 2018 Q4 | 16.23 Million INR | 2718.71% |
| 2018 Q3 | -620 Thousand INR | -113.27% |
| 2018 Q2 | 4.67 Million INR | 67.78% |
| 2017 Q2 | 1.81 Million INR | 287.58% |
| 2017 FY | - INR | 455.0% |
| 2017 Q1 | 467 Thousand INR | -90.13% |
| 2017 Q3 | 2.45 Million INR | 35.69% |
| 2017 Q4 | -208 Thousand INR | -108.47% |
| 2016 Q4 | 4.73 Million INR | 253.85% |
| 2016 Q3 | -3.07 Million INR | -1325.1% |
| 2016 FY | - INR | -27.16% |
| 2016 Q1 | 1.1 Million INR | 157.94% |
| 2016 Q2 | 251 Thousand INR | -77.26% |
| 2015 Q4 | 428 Thousand INR | -19.25% |
| 2015 FY | - INR | 15.35% |
| 2015 Q3 | 530 Thousand INR | 11.58% |
| 2015 Q2 | 475 Thousand INR | -66.9% |
| 2015 Q1 | 1.43 Million INR | -58.65% |
| 2014 Q3 | 269 Thousand INR | 15.45% |
| 2014 FY | - INR | 44.75% |
| 2014 Q1 | 1.85 Million INR | 542.27% |
| 2014 Q2 | 233 Thousand INR | -87.47% |
| 2014 Q4 | 3.47 Million INR | 1190.02% |
| 2013 Q4 | -420.33 Thousand INR | -233.44% |
| 2013 FY | - INR | 16.07% |
| 2013 Q1 | 693 Thousand INR | 3091.64% |
| 2013 Q2 | 2 Million INR | 189.47% |
| 2013 Q3 | 315 Thousand INR | -84.3% |
| 2012 Q1 | 390 Thousand INR | 172.73% |
| 2012 Q2 | 243 Thousand INR | -37.69% |
| 2012 FY | - INR | 361.64% |
| 2012 Q3 | 622 Thousand INR | 155.97% |
| 2012 Q4 | 21.71 Thousand INR | -96.51% |
| 2011 FY | - INR | -218.51% |
| 2011 Q3 | 296 Thousand INR | 0.0% |
| 2011 Q4 | 143 Thousand INR | -51.69% |
| 2010 FY | - INR | -28.97% |
| 2010 Q4 | 429 Thousand INR | 0.0% |
| 2009 Q4 | 180 Thousand INR | 0.0% |
| 2009 FY | - INR | -65.56% |
| 2008 FY | - INR | 0.0% |
| 2008 Q4 | 189 Thousand INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biocon Limited | 41.52 Billion INR | 99.976% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | 99.558% |
| Concord Biotech Limited | 4.65 Billion INR | 99.783% |
| Dishman Carbogen Amcis Limited | 3.07 Billion INR | 99.67% |
| FERMENTA BIOTECH LIMITED | 262.68 Million INR | 96.146% |
| GENOMIC VALLEY BIOTECH LIMITED | 147.4 Thousand INR | -6768.292% |
| Lyka Labs Limited | 167.58 Million INR | 93.959% |
| Panacea Biotec Limited | -200.6 Million INR | 105.047% |
| SAMSRITA LABS LIMITED | -2.46 Million INR | 511.469% |
| Servoteach Industries Limited | - INR | -Infinity% |
| SMS Lifesciences India Limited | 349.41 Million INR | 97.103% |
| Supriya Lifescience Limited | 1.83 Billion INR | 99.449% |
| Syngene International Limited | 10.84 Billion INR | 99.907% |
| TAKE Solutions Limited | -1.05 Billion INR | 100.963% |
| Titan Biotech Limited | 360.29 Million INR | 97.19% |
| Transgene Biotek Limited | -4.33 Million INR | 333.326% |
| Vanta Bioscience Limited | 14.19 Million INR | 28.659% |